Table 1.
Authorised cannabis-based medicines in the EU member states in 2018
| INN Form | Description | Availability | Indications Strength of evidence | Reference |
|---|---|---|---|---|
| Most EU member states except: | ||||
| Nabiximols Sublingual spray |
Extract of cannabis: Δ9-THC and CBD |
Bulgaria Cyprus Greece Hungary Latvia Romania Slovakia |
Muscle spasm in multiple sclerosis Moderate |
1, 24 |
| Dronabinol Capsule |
Synthetic Δ9-THC | Croatia Denmark France Ireland Poland Slovenia Spain Sweden |
AIDS related wasting Weak; Little evidence available about stimulation of appetite in people with other conditions |
1, 25 |
| Nabilone Capsule |
Synthetic cannabinoid, similar to Δ9-THC | Austria Croatia Denmark Ireland Germany Poland Slovenia Spain United Kingdom |
Nausea and vomiting associated with cancer chemotherapy Weak |
1, 26 |
| Cannabidiol Oral solution |
Extract of cannabis: CBD | Authorised for use in all EU member states in 2019 asorphan medicinal product | Intractable childhood epilepsy (Lennox-Gastaut syndrome or Dravet syndrome) Moderate |
22, 23 |
INN – international nonproprietary name